What's new

Human medicines European public assessment report (EPAR): Calquence, acalabrutinib, Date of authorisation: 05/11/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Calquence, acalabrutinib, Date of authorisation: 05/11/2020, Revision: 9, Status: Authorised

May 27, 2025 - 13:35
 0
Human medicines European public assessment report (EPAR): Calquence, acalabrutinib, Date of authorisation: 05/11/2020, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Calquence, acalabrutinib, Date of authorisation: 05/11/2020, Revision: 9, Status: Authorised
Read More

Tags:

Previous Article

PSUSA/00010355/202409

Next Article

Quality of medicines questions and answers: Part 1

Related Posts

Human medicines European public assessment report (EPAR): Galafold, migalastat, Date of authorisation: 25/05/2016, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR...

May 27, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Fasenra, Benralizumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Gastroentology-Hepatology, PIP number: P/0038/2022

Opinion/decision on a Paediatric investigation plan (PI...

May 20, 2025  0

Human medicines European public assessment report (EPAR): Accofil, filgrastim, Date of authorisation: 17/09/2014, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR...

May 16, 2025  0